ImmunoGen: Further Upside In 2017

Shares of ImmunoGen (NASDAQ:IMGN) have more than tripled year to date, as the small biotech firm has managed to strengthen its balance sheet through deal collaborations as well as demonstrate initial signs of activity for an early-stage clinical candidate.

ChartIMGN data by YCharts

Potential in Mirvetuximab Soravtansine Program

The company's lead clinical candidate is being tested in patients with folate receptor alpha (FR?)-positive ovarian cancer, with the plan later on to expand into other indications (non-small cell lung cancer, endometrial and triple negative breast cancer). In recurrent ovarian cancer, management believes there's an attractive niche to target as the need exists for more effective treatments with attractive safety profiles. There are an estimated 7,500 to 9,000 platinum-sensitive patients in second-line recurrent ovarian cancer and 19,000 to 24,000 platinum-resistant patients. Mirvetuximab soravtansine could potentially hit the market by 2020 if approved as a monotherapy, with combination regimens and other indications to follow after.

READ FULL ARTICLE HERE